SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator sunspotter
Search This Board:
Last Post: 10/9/2015 5:35:33 AM - Followers: 150 - Board type: Free - Posts Today: 5

RCHA Patent for Treatment of Hodgkin’s Lymphoma
Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma, utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
RCHA Recent News
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014.  In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases.  Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life.  Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities.  Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:


Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells (WBC) in patients depleted of these elements due to various conditions. 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs, and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000. Based on this incidence,the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003



Daily View

Weekly View

3 Month Daily View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RCHA News: Current Report Filing (8-k) 06/29/2015 04:29:11 PM
RCHA News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 06/29/2015 11:07:55 AM
RCHA News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 06/29/2015 09:56:25 AM
RCHA News: Securities Registration: Employee Benefit Plan (s-8) 06/18/2015 05:16:57 PM
RCHA News: Current Report Filing (8-k) 06/17/2015 05:08:23 PM
#6618  Sticky Note "in the face of the massive gains we sunspotter 03/17/15 05:07:01 AM
#8253   So it means that there's hope for potentials CashCassone 10/09/15 02:35:21 AM
#8252   Nah, it's a serious offense to reproduce lies sunspotter 10/09/15 02:23:29 AM
#8251   Please sticky the news. Thanks Axeman 10/09/15 12:12:38 AM
#8248   It may not be a bad idea to jonestint 10/08/15 01:46:18 PM
#8247   BMAK showing true size lets see TheTradingNinja 10/08/15 01:04:32 PM
#8246   In some .0001s 2M Lotto TheTradingNinja 10/08/15 01:04:19 PM
#8245   just posting the info, accumulation happening and shares onthegreen 10/08/15 10:29:00 AM
#8244   Just when I think the stock is going jnkirk1974 10/08/15 10:12:17 AM
#8243   "BEVERLY HILLS, Calif., Oct. 7, 2015 /PRNewswire/ -- sunspotter 10/08/15 09:57:20 AM
#8242   BEVERLY HILLS, Calif., Oct. 7, 2015 /PRNewswire/ -- onthegreen 10/08/15 09:54:43 AM
#8241   "they did announce they had applied for an sunspotter 10/08/15 07:19:50 AM
#8240   625 million shares @ .0002 sold to onthegreen 10/07/15 04:31:02 PM
#8239   Don't think he sold paper under 0001? onthegreen 10/07/15 03:21:58 PM
#8238   Bid gone. Ben and the toxic dumpers taking Axeman 10/07/15 02:36:45 PM
#8237   Pump..Nothing much. Going back to .0001 Stock Predictor 10/07/15 02:31:45 PM
#8236   Time and lots of other updates onthegreen 10/07/15 02:20:16 PM
#8235   we have a bid again thanks JC! Axeman 10/07/15 02:00:54 PM
#8234   Gonna need alot more PR's to move this.....Diluted onthegreen 10/07/15 02:00:31 PM
#8233   smart R U buying any? look at the SmokeSignals 10/07/15 01:40:20 PM
#8232   This would have been great news before the onthegreen 10/07/15 01:26:58 PM
#8231   PR was just a pump imo to sell Axeman 10/07/15 01:04:01 PM
#8230   Volume is picking up... PPS has not moved!!! Revorising 10/07/15 01:01:02 PM
#8229   WHEN DID THAT NEWS COME OUT? [SMART MONEY] 10/07/15 12:54:40 PM
#8228   I think people are fed up here. Give jonestint 10/07/15 11:48:57 AM
#8227   yes, but why no response from the market, badshah 10/07/15 11:23:30 AM
#8226   Does anyone remember my posts about updates in jonestint 10/07/15 10:44:30 AM
#8225   These crooks can't seem to keep their lies straight. sunspotter 10/07/15 10:06:32 AM
#8224   Rich Pharmaceuticals Retains Theradex Systems To Finalize Investigational cash4 10/07/15 09:54:25 AM
#8223   BEVERLY HILLS, Calif., Oct. 7, 2015 /PRNewswire/ -- GoHighOrGoHigh 10/07/15 09:52:14 AM
#8222   Someone knows something. The volume speaks for itself! Earache 10/06/15 06:10:13 PM
#8221   Sounds like,a lot of bs. Good luck to brando5 10/06/15 12:26:56 PM
#8220   I fail to see your point. Mine is Long-vestor 10/06/15 12:11:44 PM
#8219   Yea I see the deception and shadiness possibility brando5 10/06/15 11:19:26 AM
#8218   There's no millions being made here at .0001 brando5 10/06/15 11:15:08 AM
#8217   Ha that's what they all do! That's why brando5 10/06/15 11:12:10 AM
#8216   Huge reverse then down it goes more as brando5 10/06/15 11:11:30 AM
#8214   Wow OS now 3.5 Billion from 417 million Axeman 10/01/15 10:57:34 AM
#8213   Wow! Did you see that 10k.. Complete scam Chebaccastocks 10/01/15 09:54:08 AM
#8211   "Apparently a clearer explanation is required for my statement" sunspotter 09/30/15 11:56:18 AM
#8210   "What you call "pipe dream" is actually a Long-vestor 09/30/15 11:50:33 AM
#8207   "Actually there's not much in the 10Q that's wrong" sunspotter 09/30/15 06:43:23 AM
#8206   Looks like they are fully reporting/ current now. Revorising 09/29/15 11:07:01 PM
#8205   "It's an offense to re-publish inaccurate and Long-vestor 09/29/15 06:12:34 PM
#8204   CEO sold BILLIONs of shares over the past onthegreen 09/29/15 03:42:46 PM
#8203   No Proof but thanks. Someone was tired of Axeman 09/29/15 11:44:09 AM
#8202   Is there lots of convertible debt? What's market brando5 09/29/15 11:41:01 AM
#8201   Where's the proof that Chang dumped shares? jonestint 09/29/15 11:37:05 AM
#8200   Chang finally dumped the 1's. Game over....R/S very onthegreen 09/29/15 11:22:13 AM
#8199   Honestly i agree that it looks terrible, but Revorising 09/26/15 11:21:42 AM
#8195   "Mods please sticky 10k" sunspotter 09/25/15 07:16:26 AM